Assessing the Benefits of GLP-1 RAs

Older lady talking with her doctor.

Improving Cardiac and Renal Well-being

GLP-1 RAs are injectable glucose-lowering medications approved by the FDA for the treatment of adult patients with T2DM. In addition, GLP-1 RAs have been identified as an important drug class for not only glucose-lowering but also in reducing cardiovascular disease (CVD) events in adults with T2DM and high atherosclerotic cardiovascular disease (ASCVD) risk.1

GLP-1 RAs stimulate glucose-dependent insulin release in the gut after food intake and inhibit glucagon release with concomitant decreased gastric emptying and low risk of hypoglycemia. Important secondary effects include a decrease in appetite and food intake, which can lead to weight loss of 2 to 4 kg, and improved lipid levels, with decreased triglyceride levels and increased high-density lipoprotein levels.

Game Changers – The game that invites you to test your knowledge of GLP-1 RAs

It's time to test your knowledge about GLP-1 RAs and their benefits as they relate to type 2 diabetes.

Categories range from diagnostic criteria to Lifestyle Management. Test your knowledge and find out with this fun, engaging game.

Test Your Knowledge of GLP-1 RAs
Innovation and new ideas lightbulb concept with a question mark

Vodcast Series

GLP-1 RAs: What You Need To Know

Putting evidence into practice: Tips for starting and continuing GLP-1 RAs

Conversation around how a cardiologist or non-endocrinologist starts GLP-1 RAs. We will explore dose escalation, concerns about hypoglycemia, managing other glucose lowering agents, how to deal with adverse effects and other important topics. Claim CE Credit
Claim Credit: Putting Evidence Into Practice

Episode 7: Barriers to GLP-1 RAs

Conversation around the barriers to GLP-1 RAS. Dr. Trudy Gaillard and Dr. Monica Peek discuss adverse effects, cost, strategies when taking with other medications, social determinants of health, and educational support. Claim CE and MOC Credit
Earn Credit: Barriers to GLP-1 RAs

Selecting the Right Patient at the Right Time

Conversation around patient selection and GLP-1 RAs. The speakers will explore the effects of GLP-1 RAs and SGLT-2 inhibitors on clinical outcomes and CVD risk factors. Claim CE Credit
Claim Credit: Selecting the Right Patient at the Right Time

Practical Pointers to Optimize the Use of GLP-1 RAs

Conversation about the approved GLP-1 RAs to manage type 2 diabetes mellitus (T2DM). Forms of administration, contextualizing the many benefits and the risks, and indications will be discussed. Claim CE Credit
Claim Credit: Practical Pointers to Optimize the Use of GLP-1 RAs

Chronic Kidney Disease and GLP-1 RAs

Discussion on the use of GLP-1 RAs in individuals with type 2 diabetes and chronic kidney disease (CKD), covering general diabetes management in CKD, potential benefits of GLP-1 RA therapy, and contemporary guideline recommendations for GLP-1 RA use in this population.
Claim Credit: Chronic Kidney Disease and GLP-1 RAs

Cardiovascular Benefits of GLP-1 RAs

Conversation around specific cardiovascular risks, while distinguishing between glycemic control and cardiovascular risk reduction. We will also highlight the benefits of treatment with GLP-1 RA in patients with diabetes. Claim CE and MOC Credit
Claim Credit: Cardiovascular Benefits of GLP-1RAs

Demystifying GLP-1s

This activity focuses on the American Heart Association’s Essential 8 and glucose control. You will learn how GLP-1 RAs accelerate these glucose control goals and contribute to cardiorenal outcomes including how they work. Claim CE and MOC Credit
Claim Credit: Demystifying GLP-1s

Obesity and GLP-1 RAs

Conversation about the global rise of obesity and its association with diabetes and the limited effectiveness of many pharmacotherapies tested for management of obesity. Claim CE Credit
Claim Credit: Obesity and GLP-1 RAs

References

1Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140: e596–e646. DOI: 10.1161/CIR. 0000000000000678

This program is supported by a medical educational grant from Novo Nordisk.